BUZZ — Sandoz seen rising after it secures Canada approval for generic GLP — 1 shot

* Shares in Sandoz are indicated to rise 3% pre-market after Swiss generic drugmaker received regulatory approval for its generic semaglutide to treat type-2 diabetes in Canada * The injection is a generic version of Novo Nordisk's GLP-1 drug Ozempic, Sandoz says * The approval does not affect Sandoz's 2026 financial guidance, and it expects no material contribution this year from any potential launches of the drug * Canadian GLP-1 market is worth $2.6 billion, with close to 12 million semaglutide injection pens issued annually, the company says (Reporting by Amir Orusov) ((Amir.orusov@thomsonreuters.com)